The Conversation (0)
iCo Therapeutics Inc. has announced its financial results for the quarter ended September 30, 2015. According to the press release: “As we continue to progress our oral delivery platform for Amp B we’ve also seen iCo-008 value building via our partner progressing systemic use indications, including a recently announced IND in the United States,” said Andrew …
iCo Therapeutics Inc. has announced its financial results for the quarter ended September 30, 2015.
According to the press release:
“As we continue to progress our oral delivery platform for Amp B we’ve also seen iCo-008 value building via our partner progressing systemic use indications, including a recently announced IND in the United States,” said Andrew Rae, President & CEO of iCo Therapeutics. “These advancements regarding iCo-008 are not only value enriching for this clinical program, but also continue to give us confidence in its potential therapeutic application in ophthalmological indications.”
Subsequent Events to Quarter End
Announced manufacturing update for Amp B wherein iCo engaged Corealis Pharma Inc., a contract manufacturing organizing, for analytical development, formulation optimization and scale-up of the Amp B oral delivery system. Preparation and regulatory filings are expected to be complete in 2016, and Phase 1A study data is expected to be available in 2017. Further strengthened intellectual property around the oral delivery platform for Amp B with a recent issuance of a composition of matter and use patent, bringing the total number of issued patents to eleven. We continue to pursue additional issuances in multiple jurisdictions.
Click here to read the full press release.